

Press Release



Notification regarding the acquisition of DroEthi® Combination Tablets' marketing authorization for Dysmenorrhea

TOKYO, February 15th, 2022 - ASKA Pharmaceutical Co., Ltd. (Headquarter: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Headquarter: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi), announced today that DroEthi® Combination Tablets (Drospirenone/ Ethinylestradiol) acquired marketing authorization for the treatment of dysmenorrhea.

DroEthi® Combination Tablets is the first generic drug in Japan to combine Drospirenone/ Ethinylestradiol as a low-dose estrogen/progestin combination drug.

Dysmenorrhea is associated with menstruation characterized by a group of symptoms, such as severe lower abdominal and lower back pain that affects women's quality of life. DroEthi® is expected to provide a new treatment option for women suffering from such symptoms and contribute to reducing the economic burden of patients.

ASKA Pharmaceutical Co., Ltd. will continue to make the utmost efforts to prepare for the launch of DroEthi® after NHI drug price listing.

Summary of authorization

Product name : DroEthi® Combination Tablets

Generic name : Drospirenone/ Ethinylestradiol

Indication : Dysmenorrhea

Dosage and Administration :

One tablet a day is orally administered at a specified time every day. The drug is to be taken in the specified order (Beginning with the light red tablets) for 28 consecutive days.

One administration cycle is to be 28 days, and regardless of whether bleeding has stopped or not, start the next administration cycle on the 29th day.

Repeat the above administration cycle as indicated.

Origin of the name :

DroEthi® is a generic unified brand name for the generic combination drug of Drospirenone/ Ethinylestradiol.

About ASKA Pharmaceutical Co., Ltd.

ASKA celebrated its 100th anniversary in 2020 and inaugurated a holding company structure in April 2021. ASKA contributes to the medical community as a specialty pharma company emphasizing in three therapeutic areas of internal medicine, obstetrics and gynaecology, and urology. ASKA is focusing on developing new drugs as well as medical devices to address unmet medical needs and to offer new treatment methods.

For more information, please visit our website at <https://www.aska-pharma-hd.co.jp/english/>.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp